DLG4 and Stroke: Recently, in a multicentre trial, the NA-1 peptide produced a significant improvement among stroke patients that did not receive t-PA, while unexpectedly, this PSD95 inhibitor did not show favorable outcomes in t-PA-treated stroke patients [14].